Target validation in drug discovery = 药物发现中的靶标确认 / Brian W. Metcalf and Susan Dillon. —[Reprinted ed.]. — Beijing : Science Press ; [Amsterdam] : Elsevier, 2007.—(63.326/M588(R))

Contents

    CONTENTS
    
    PREFACE vii
    CONTRIBUTORS xi
    Ⅰ PHARMACEUTICAL BIOTECHNOLOGY FOR TARGET VALIDATION I
    1 Generation of Transgenic Animals 3
    2 Target Validation in Chemogenomics 27
    Ⅱ TARGET VALIDATION FOR BIOPHARMACEUTICAL DRUG DISCOVERY 41
    3 Cetuximab (Erbitux)， An Anti-Epidermal Growth Factor Receptor Antibody for the Treatment of Metastatic Colorectal Cancer 43
    4 Monoclonal Antibody to HER-2 in Breast Cancer 69
    5 Validation of TNF as a Drug Target in Inflammatory Bowel Disease 83
    6 Anti-CCL-2/MCP-I: Directed Biologicals for Inflammatory and Malignant Diseases 103
    7 Targeting IL-12p40 for Immune-Mediated Disease 12 I
    8 The GPllb/llla Antagonist Abciximab for Acute Percutaneous Coronary Intervention 135
    Ⅲ VALIDATING TARGETS OF SMALL MOLECULE APPROACHES 153
    9 Epidermal Growth Factor Receptor(EGFR) Inhibitor for Oncology: Discovery and Development of Erlotinib 155
    10 Progress in Achieving Proof of Concept for p38 Kinase Inhibitors 179
    11 IKK-2/NF-KB-Dependent Transcription 199
    12 TNF Signaling Pathway Inhibitors for Inflammation-CCR2 Antagonists 223
    13 The Discovery of Eltrombopag， An Orally Bioavailable TpoR Agonist 241
    14 Orally Bioavailable Glycoprotein llb/llla Antagonists: A Negative Case Study 255
    INDEX 269